← Back to Search

Monoclonal Antibodies

ANX005 for Autoimmune Hemolytic Anemia

Phase 2

Waitlist Available

Led By Morie Gertz, MD

Research Sponsored by Annexon, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to day 71

Awards & highlights

Study Summary

This trial will test a new drug, ANX005, for people with Warm Autoimmune Hemolytic Anemia. They will evaluate how safe and tolerable the drug is.

Eligible Conditions

Warm Autoimmune Hemolytic Anemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to day 71

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to day 71

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 71 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in disease activity biomarkers

Safety: Treatment-emergent adverse events (TEAEs)

Secondary outcome measures

Change in complement system biomarkers

Plasma concentrations

Trial Design

1Treatment groups

Experimental Treatment

Group I: ANX005Experimental Treatment1 Intervention

Participants will receive two once-weekly doses of ANX005 at specific time points

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ANX005

2020

Completed Phase 2

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor

12 Previous Clinical Trials

792 Total Patients Enrolled

Morie Gertz, MDPrincipal InvestigatorMayo Clinic, Rochester, MN

Study DirectorStudy DirectorAnnexon, Inc.

1,208 Previous Clinical Trials

489,689 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is ANX005 reported to be risk-free for individuals?

"The safety rating for ANX005 was determined to be 2 out of 3, given the lack of evidence confirming its efficacy from Phase 2 trials."

Answered by AI

Are there any vacancies to partake in this investigation?

"Based on the information found at clinicaltrials.gov, this study is accepting applicants and was initially posted in November 2021 with updates occurring as recently as June 2022."

Answered by AI

How many enrollees are currently partaking in this scientific investigation?

"Affirmative. The clinical trial records located on clinicaltrials.gov attest that this particular study was first posted in November 10th 2021 and modified last June 21st 2022 looking for 12 patient volunteers from a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

2021. "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04691570.